Carbapenem-resistant Gram-negative bacteria: how to prioritize infection prevention and control interventions in resource-limited settings?

Expert Rev Anti Infect Ther. 2013 Feb;11(2):147-57. doi: 10.1586/eri.12.164.

Abstract

Emergences of carbapenem-resistant Gram-negative bacteria (CRGNB) have heightened global awareness of the prioritization of infection prevention and control (IPC) interventions to minimize infections attributed to these bacteria. Effective new antibiotic drugs for CRGNB are estimated to be at least 5 years off completion of trials and approval for use. Hence, effective IPC strategies remain at the core of clinical care and research for patients with CRGNB infection. The authors summarize current evidence and viewpoints for IPC strategies as related to the emergence, transmission and prevention of CRGNB.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter baumannii / drug effects
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Carbapenems / pharmacology
  • Carbapenems / therapeutic use*
  • Communicable Disease Control / economics
  • Communicable Disease Control / methods
  • Drug Resistance, Bacterial
  • Enterobacteriaceae / drug effects
  • Gram-Negative Bacteria / drug effects
  • Gram-Negative Bacterial Infections / drug therapy
  • Gram-Negative Bacterial Infections / epidemiology
  • Gram-Negative Bacterial Infections / prevention & control*
  • Humans
  • Incidence
  • Pseudomonas aeruginosa / drug effects

Substances

  • Anti-Bacterial Agents
  • Carbapenems